ERBB2 TMD/JMD mutants bind trastuzumab

Stable Identifier
R-HSA-9665696
Type
Reaction [binding]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The following ERBB2 TMD/JMD mutants are sensitive to the therapeutic antibody trastuzumab (herceptin):
ERBB2 V659E (Pahuja et al. 2018);
ERBB2 G660D (Pahuja et al. 2018);
ERBB2 G660R (Pahuja et al. 2018);
ERBB2 R678Q (Bose et al. 2013, Pahuja et al. 2018);
ERBB2 Q709L (Pahuja et al. 2018);
Literature References
PubMed ID Title Journal Year
30449325 Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations

Antony, A, Khanna-Gupta, A, Singh, A, Pahuja, KB, Kljavin, NM, Bueno, R, Chougule, A, Dutt, A, Phalke, S, Prabhash, K, Gupta, R, Ziai, J, Banavali, SD, Kumar, P, Trivedi, V, Seshagiri, S, Jaiswal, BS, Nguyen, TT, DeGrado, WF, Ramprasad, V, Vargas, D, Senger, K, Chaudhuri, S, Sokol, ES, Trabucco, SE, Patil, V, Joshi, A, Thaker, TM, Noronha, V, Hartmaier, RJ, Durinck, S, Mravic, M, Stawiski, EW, Jura, N

Cancer Cell 2018
23220880 Activating HER2 mutations in HER2 gene amplification negative breast cancer

Bose, R, Shen, W, Aronson, AB, Goel, N, Koboldt, DC, Li, S, Searleman, AC, Ma, CX, Ellis, MJ, Shen, D, Ding, L, Monsey, J, Mardis, ER, Kavuri, SM

Cancer Discov 2013
Participants
Participates
Normal reaction
Functional status

Gain of function of ERBB2 TMD/JMD mutants (trastuzumab):ERBIN:HSP90:CDC37 [plasma membrane]

Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!